Journal of Hepatology最新文献

{"title":"Introducing the Updates in Clinical Science: A focus on recent data of high impact","authors":"Vlad Ratziu, Tom H. Karlsen","doi":"10.1016/j.jhep.2024.12.007","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.12.007","url":null,"abstract":"No Abstract","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"31 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142869989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differences between hepatocellular carcinoma caused by alcohol and other aetiologies","authors":"Nathalie Ganne-Carrié, Pierre Nahon","doi":"10.1016/j.jhep.2024.12.030","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.12.030","url":null,"abstract":"Alcohol-related liver disease is the third cause of hepatocellular carcinoma worldwide and the leading cause in Europe. Additionally, the recent definition of Metabolic dysfunction-Associated Steatotic Liver Disease with increased alcoholic intake will enrich this population with a more nuanced phenotype, reflecting recent epidemiological trends. In these patients, hepatocellular carcinoma diagnosis is often delayed and less frequently detected through screening programs. Moreover, at the time of diagnosis, patients with alcohol-related hepatocellular carcinoma tend to have a poorer general condition, more severely impaired liver function, and a higher prevalence of comorbidities, leading to increased competitive mortality.However, when hepatocellular carcinoma is diagnosed during surveillance programs in patients with alcohol-related liver disease or metabolic dysfunction-Associated steatotic liver disease with increased alcoholic intake, the rate of allocation to first-line curative treatments is high (56%) and comparable to that of patients with virus-related hepatocellular carcinoma. As a consequence, the etiology of the underlying cirrhosis cannot be considered an independent prognostic factor in patients with hepatocellular carcinoma. Instead, prognosis is driven by liver function, general condition, and tumor burden. This underscores the crucial role of early diagnosis through periodic surveillance in patients with Alcohol-related liver disease or Metabolic dysfunction-Associated Steatotic Liver Disease with increased alcoholic intake -related cirrhosis.","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"24 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142867148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RORc expressing immune cells negatively regulate tertiary lymphoid structure formation and support their pro-tumorigenic functions","authors":"Einat Cinnamon, Ilan Stein, Elvira Zino, Stav Rabinovich, Yehuda Shovman, Yehuda Schlesinger, Tomer-Meir Salame, Shlomit Reich-Zeliger, Thomas Albrecht, Stephanie Roessler, Peter Schirmacher, Michal Lotem, Yinon Ben-Neriah, Oren Parnas, Eli Pikarsky","doi":"10.1016/j.jhep.2024.12.015","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.12.015","url":null,"abstract":"<h3>Background and aims</h3>RORc-expressing immune cells play important roles in inflammation, autoimmune disease and cancer. They are required for lymphoid organogenesis and have been implicated in tertiary lymphoid structure (TLS) formation. TLSs are formed in many cancer types and have been correlated with better prognosis and response to immunotherapy. In liver cancer, some TLSs are pro-tumorigenic as they harbor tumor progenitor cells and support their growth. The processes involved in TLS development and acquisition of pro- or anti-tumorigenic roles are largely unknown. This study aims to explore the role of RORc-expressing cells in TLS development in the context of inflammation-associated liver cancer.<h3>Methods</h3>IKKβ(EE)^Hep mice, exhibiting chronic liver inflammation, TLS formation and liver cancer, were crossed with RORc knockout mice to explore RORc’s effect on TLS and tumor formation. TLS phenotypes were analyzed using transcriptional, proteomic, and immunohistochemical techniques. CD4, CD8, and B cell depletions were used to assess their contribution to liver TLS and tumor formation.<h3>Results</h3>RORc-expressing cells are detected within TLSs of both human patients and mice developing intrahepatic cholangiocarcinoma. In mice, these cells negatively regulate TLS formation, as excess TLSs form in their absence. CD4 cells are essential for liver TLS formation, while B cells are required for TLS formation specifically in the absence of RORc-expressing cells. Importantly, in chronically inflamed livers lacking RORc-expressing cells, TLSs become anti-tumorigenic, reducing tumor load. Anti-tumorigenic TLSs revealed enrichment of exhausted CD8 cells with effector functions, germinal center B cells and plasma cells. B cells are key in limiting tumor development, possibly via tumor-directed antibodies.<h3>Conclusions</h3>RORc-expressing cells negatively regulate B cell responses and facilitate the pro-tumorigenic functions of hepatic TLSs.","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"89 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142867149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AI model using CT-based imaging biomarkers to predict hepatocellular carcinoma in patients with chronic hepatitis B","authors":"Hyunjae Shin, Moon Haeng Hur, Byeong Geun Song, Soo Young Park, Gi-Ae Kim, Gwang Hyun Choi, Joon Yeul Nam, Minseok Albert Kim, Youngsu Park, Yunmi Ko, Jeayeon Park, Han Ah Lee, Sung Won Chung, Na Ryung Choi, Min Kyung Park, Yun Bin Lee, Dong Hyun Sinn, Seung Up Kim, Hwi Young Kim, Jong-Min Kim, Jeong-Hoon Lee","doi":"10.1016/j.jhep.2024.12.029","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.12.029","url":null,"abstract":"<h3>Background &amp; aims</h3>Various hepatocellular carcinoma (HCC) prediction models have been proposed for patients with chronic hepatitis B (CHB) using clinical variables. We aimed to develop an artificial intelligence (AI)-based HCC prediction model by incorporating imaging biomarkers derived from abdominal computed tomography (CT) images along with clinical variables.<h3>Methods</h3>An AI prediction model employing a gradient-boosting machine algorithm was developed utilizing imaging biomarkers extracted by DeepFore, a deep learning-based CT auto-segmentation software. The derivation cohort (n=5,585) was randomly divided into the training and internal validation sets at a 3:1 ratio. The external validation cohort included 2,883 patients. Six imaging biomarkers (i.e., abdominal visceral fat–total fat volume ratio, total fat–trunk volume ratio, spleen, and liver volume; liver–spleen Hounsfield unit [HU] ratio; and muscle HU) and eight clinical variables were selected as the main variables of our model, PLAN-B-DF.<h3>Results</h3>In the internal validation set (median follow-up duration=7.4 years), PLAN-B-DF demonstrated an excellent predictive performance with a c-index of 0.91 and good calibration function (<em>P</em>=0.78 by the Hosmer-Lemeshow test). In the external validation cohort (median follow-up duration=4.6 years), PLAN-B-DF showed a significantly better discrimination function compared to previous models including PLAN-B, PAGE-B, modified PAGE-B, and CU-HCC (c-index, 0.89 vs. 0.65—0.78; all <em>P</em>&lt;0.001) and maintained a good calibration function (<em>P</em>=0.42 by the Hosmer-Lemeshow test). When patients were classified into four groups according to the risk probability calculated by PLAN-B-DF, the 10-year cumulative HCC incidence was 0.0%, 0.4%, 16.0%, and 46.2% in the minimal-, low-, intermediate-, and high-risk groups, respectively.<h3>Conclusion</h3>This AI prediction model, integrating deep learning-based auto-segmentation of CT images, offers improved performance in predicting HCC risk among patients with CHB compared to previous models.<h3>Impact and implications</h3>The AI-driven HCC prediction model (PLAN-B-DF), employing an automated CT segmentation algorithm, demonstrates a significant improvement in predictive accuracy and risk stratification among patients with CHB. Using a gradient-boosting algorithm and CT metrics such as visceral fat volume and myosteatosis, PLAN-B-DF outperforms previous models based solely on clinical and demographic data. This model not only shows a higher c-index compared to previous models, but also effectively classifies CHB patients into different risk groups. This model uses machine learning to analyze the complex relationships among various risk factors contributing to HCC occurrence, thereby offering more personalized surveillance for CHB patients.","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"64 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142857698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and efficacy of GLP-1/FGF21 dual agonist HEC88473 in MASLD and T2DM: a randomized, double-blind, placebo-controlled study","authors":"Lin Xiang, Guixia Wang, Yulei Zhuang, Lin Luo, Jiangyu Yan, Hong Zhang, Xiaojiao Li, Can Xie, Qingwei He, Yuyu Peng, Hong Chen, Qianqian Li, Xiaoping Li, Linfeng Guo, Guoyue Lv, Yanhua Ding","doi":"10.1016/j.jhep.2024.12.006","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.12.006","url":null,"abstract":"<h3>Background and Aims</h3>Glucagon-like peptide-1 (GLP-1) and fibroblast growth factor 21 (FGF21) are key regulators of glucose and lipid metabolism. In the present study, we assessed the safety and efficacy of a novel GLP-1/FGF21 dual agonist HEC88473 for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD) combined with type 2 diabetes mellitus (T2DM).<h3>Methods</h3>This was a randomized, double-blind, placebo-controlled, multiple-ascending-dose phase 1b/2a trial. Sixty patients with MASLD and T2DM were randomized (10:2) to receive HEC88473 (5.1, 15.3, 30.6, 45.9, or 68.0 mg) or placebo via weekly subcutaneous injection for 5 weeks.<h3>Results</h3>After 5 weeks of treatment with HEC88473, the magnetic resonance imaging proton-density fat fraction (MRI-PDFF) was reduced in a dose-proportional manner. The largest relative mean change reached −47.21% (<em>P</em> = 0.0143) in the 30.6 mg cohort, as compared with −15.05% in the placebo group, with proportions of &gt; 30% relative reduction higher in patients with baseline PDFF &gt; 8%. The 5-week treatment with HEC88473 significantly reduced levels of glycated hemoglobin (HbA1c) as well as fasting and postprandial glucose levels. The largest mean change in HbA1c reached −1.10% in the 68.0 mg cohort, as compared with −0.31% in the placebo group. Improvement was also observed in participants’ lipid profiles. Most adverse events (AEs) were mild-to-moderate in severity. The most frequently reported AEs were gastrointestinal disorders (n = 29, 48.3%).<h3>Conclusions</h3>Herein, we report the clinical safety and proof of concept data for the GLP-1/FGF21 dual agonist HEC88473. A 5-week treatment with HEC88473 was generally safe and well tolerated, with multiple positive effects observed, including reduced liver fat, and improved glycemic control, insulin resistance and lipid metabolism, together indicating comprehensive improvement in metabolic syndrome.<h3>Clinical Trial Number</h3>Chinese Drug Trial Identifier (<span><span>http://www.chinadrugtrials.org.cn/index.html</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>): CTR20211088;ClinicalTrials.govNCT05943886","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"31 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142849240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single-cell RNA seq-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma","authors":"Sarah Cappuyns, Marta Piqué-Gili, Roger Esteban-Fabró, Gino Philips, Ugne Balaseviciute, Roser Pinyol, Albert Gris-Oliver, Vincent Vandecaveye, Jordi Abril-Fornaguera, Carla Montironi, Laia Bassaganyas, Judit Peix, Marcus Zeitlhoefler, Agavni Mesropian, Júlia Huguet-Pradell, Philipp K. Haber, Igor Figueiredo, Giorgio Ioannou, Edgar Gonzalez-Kozlova, Antonio D’Alessio, Josep M. Llovet","doi":"10.1016/j.jhep.2024.12.016","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.12.016","url":null,"abstract":"<h3>Background &amp; Aims</h3>The combination of atezolizumab and bevacizumab (atezo+bev) is the current standard of care for advanced hepatocellular carcinoma (HCC), providing a median overall survival (OS) of 19.2 months. Here, we aim to uncover the underlying cellular processes driving clinical benefit versus resistance to atezo+bev.<h3>Methods</h3>We harnessed the power of single-cell RNA sequencing in advanced HCC to derive gene expression signatures recapitulating 21 cell phenotypes. These signatures were applied to 422 RNA-sequencing samples of advanced HCC patients treated with atezo+bev (n=317) versus atezolizumab (n=47) or sorafenib (n=58) as comparators.<h3>Results</h3>We unveiled two distinct patterns of response to atezo+bev. First, an immune-mediated response characterized by the combined presence of CD8+ T effector cells and pro-inflammatory CXCL10+ macrophages, representing an immune rich microenvironment. Second, a non-immune, angiogenesis-related response distinguishable by a reduced expression of the VEGF co-receptor neuropilin-1 (<em>NRP1</em>), a biomarker that specifically predicts improved OS upon atezo+bev vs sorafenib (p = 0.039). Primary resistance was associated with an enrichment of immunosuppressive myeloid populations, namely CD14+ monocytes and TREM2+ macrophages, and Notch pathway activation. Based on these mechanistic insights we define \"<em>Immune-competent</em>\" and \"<em>Angiogenesis-driven</em>\" molecular subgroups, each associated with a significantly longer OS with atezo+bev versus sorafenib (p of interaction = 0.027), and a “<em>Resistant”</em> subset.<h3>Conclusion</h3>Our study unveils two distinct molecular subsets of clinical benefit to atezolizumab plus bevacizumab in advanced HCC (“<em>Immune-competent”</em> and “<em>Angiogenesis-driven”</em>) as well as the main traits of primary resistance to this therapy, thus providing a molecular framework to stratify patients based on clinical outcome and guiding potential strategies to overcome resistance.","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"28 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142857699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to the two letters to the Editor commenting our manuscript","authors":"Antonio Segovia-Zafra, M Isabel Lucena, Raul J. Andrade","doi":"10.1016/j.jhep.2024.12.020","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.12.020","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Authors' contributions</h2>All authors contributed equally to the production of this manuscript</section></section><section><section><h2>Financial support</h2>The authors did not receive any financial support to produce this manuscript.</section></section><section><section><h2>Declaration of Competing Interest</h2>The authors of this study declare that they do not have any conflict of interest.Please refer to the accompanying ICMJE disclosure forms for further details.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"247 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142832773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Carvedilol vs. propranolol for the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis","authors":"Jose Ignacio Fortea, Edilmar Alvarado-Tapias, Benedikt Simbrunner, Iranzu Ezcurra, Virginia Hernández-Gea, Carles Aracil, Elba Llop, Angela Puente, Cristina Roig, Thomas Reiberger, Juan Carlos García-Pagan, José Luis Calleja, Andreu Ferrero-Gregori, Matthias Mandorfer, Candid Villanueva, Javier Crespo","doi":"10.1016/j.jhep.2024.12.017","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.12.017","url":null,"abstract":"<h3>Background and Aims</h3>Data on the effectiveness of classical non-selective beta-blockers (cNSBB, i.e., propranolol and nadolol) versus carvedilol in patients with cirrhosis are scarce. The present study aimed to compare their potential for preventing decompensation and mortality in patients with compensated and decompensated cirrhosis.<h3>Methods</h3>Multicenter retrospective study including compensated and decompensated cirrhotic patients with clinically significant portal hypertension, undergoing measurement of hepatic venous pressure gradient (HVPG) to assess acute hemodynamic response to intravenous propranolol (i.e., HVPG decrease≥10% from baseline value) prior to primary prophylaxis for variceal bleeding. Outcomes were adjusted using Inverse Probability of Treatment Weighting (IPTW) in a competitive risk framework.<h3>Results</h3>A total of 540 patients with cirrhosis were included, 256 compensated (cNSBB n=111; carvedilol n=145) and 284 decompensated (cNSBB n=134; carvedilol n=150). Median follow-up was 36.3 (IQR 16.9-61.0) months and 30.7 (IQR 13.1-52.2) months, respectively. After covariate balancing with IPTW, carvedilol, compared to cNSBB, significantly reduced the risk of a first decompensation in compensated patients (SHR 0.61; 95% CI 0.41-0.92; p=0.019) and a combined endpoint of further decompensation/death in decompensated patients (SHR 0.57; 95% CI 0.42-0.77; p&lt;0.0001). A second HVPG was conducted on 176 (68.8%, compensated) and 177 patients (62.3%, decompensated). Acute non-responders, both compensated (11.1% vs. 29.4%; p=0.422) and decompensated (16.0% vs. 43.6%: p=0.0247) patients, showed a higher likelihood of achieving a chronic hemodynamic response with carvedilol. The safety profile of each type of NSBB was comparable in both cohorts.<h3>Conclusions</h3>Our data endorse the current recommendation favoring the use of carvedilol in the prevention of a first decompensation of cirrhosis and suggest extending the recommendation for its preferential use to patients with decompensated cirrhosis without recurrent or refractory ascites.<h3>IMPACT AND IMPLICATIONS</h3>This study addresses a gap in the comparative effectiveness of classical non-selective beta-blockers (e.g., propranolol and nadolol) versus carvedilol in managing cirrhosis in both compensated and decompensated stages. Our results support the preferential use of carvedilol in both settings due to its superior efficacy in reducing first and further decompensation. However, the retrospective nature of the study and inherent selection biases advise caution against broadly applying these findings to patients with decompensated cirrhosis who exhibit signs of circulatory dysfunction or recurrent/refractory ascites.","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"87 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142832777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing Antiviral Prophylaxis Strategies: Insights and Reflections on a Real-World Study","authors":"Shanshan Liu, Xinmin Deng, Xiaofeng Lv","doi":"10.1016/j.jhep.2024.12.024","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.12.024","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Authors' contributions</h2>All authors contributed to the study conception and design. Study design, SSL, XMD, XFL, Writing-original draft, SSL, XMD, XFL; Writing-review &amp; editing, SSL, XMD, XFL; Supervision: XFL.</section></section><section><section><h2>Financial support</h2>This research received no external funding.</section></section><section><section><h2>Declaration of Competing Interest</h2>None of the authors has any conflicts of interest.</section></section><section><section><h2>Acknowledgements</h2>None.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"30 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142832769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Not all fat is alike in MASLD","authors":"Amedeo Lonardo, Giovanni Targher","doi":"10.1016/j.jhep.2024.12.025","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.12.025","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Authors' contributions</h2>Both authors contributed equally to the ideation, drafting and revising of the present letter to the Editor.</section></section><section><section><h2>Financial support</h2>None</section></section><section><section><h2>Declaration of Competing Interest</h2>None</section></section><section><section><h2>Acknowledgements</h2>None</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"21 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142832768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}